Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860130 · ClinicalTrials.gov registry record · Phase 3
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
A Phase 3 study, sponsored by Vantive Health.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT02860130 is a Phase 3 study that was terminated before completion, run by Vantive Health. The registered enrollment target is 34 participants.
The verdict
NCT02860130, a Phase 3 study, was terminated before completion, sponsored by Vantive Health.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.
Interventions
- DRUG Prismocitrate 18
- OTHER No Anticoagulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2018-05-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02860130
The ClinicalTrials.gov registry entry for NCT02860130 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantive Health, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prismocitrate 18 is the first listed.
NCT02860130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02860130 about?
NCT02860130 is a clinical study titled "Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)". The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will...
What is the current status of trial NCT02860130?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2016-09-27. Estimated completion is 2018-05-12.
What interventions are being tested in trial NCT02860130?
The interventions under investigation include: Prismocitrate 18 (DRUG), No Anticoagulation (OTHER).
Who is sponsoring clinical trial NCT02860130?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.